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Simian virus 40 (SV40)' is a DNA virus that readily infects but does not
replicate in mouse cells (1). Although SV40-transformed cells form tumors in
immunocompromised mice and in neonatal mice, they are generally not tumor-
igenic in adult syngeneic animals (2);2 the ability to mount a cellular immune
response to epitopes of SV40 T antigen has been implicated in the control of
SV40-induced tumor cell growth in normal, immunocompetent mice (3-6).
Recently, a number of SV40-transgenic mouse lines have been derived by the
zygotic injection of various SV40 early-region gene constructs, and mice from
many, but not all ofthese lines develop tumors at specific sites (7-9). Such mice
offer an ideal system for investigating the potential role ofimmune tolerance or
responsiveness to an endogenous viral oncogene to which a normal immune
response has already been well characterized. Although immune tolerance to
transgene products has been suggested in other systems (10), no definitive
exploration ofthis phenomenon has yet been reported. We examined mice from
two SV40 transgenic lines bearing identical SV40 plasmid constructs (7) to
determine whether such mice are immunologically responsive to subsequent
challenge with SV40. We find that mice from these two lines differ in tumor
incidence, and that specific immune tolerance to SV40 T antigen is an invariant
feature of mice from the SV40 transgenic line that consistently develops tumors
expressing this viral gene product. The majority of mice from the second SV40
transgenic line that remain essentially tumor-free generate a normal cellular
immune response to SV40 after immunization with the virus.
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Materials and Methods
Mice.
￿
The two SV40 transgenic mouse lines, 419 and 427, each contain the SVMK
plasmid consisting of: a pSV3-ts58-derived Kpn I-Bam HI fragment (including the 72-
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Abbreviationsused in this paper:
￿
DME*, Dulbecco's modified Eagle'smedium supplemented with
FCS and 2-ME; SV40, simian virus 40.
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and 21-bp repeats, TATA box, and SV40 early-region coding sequence), and in the
opposite orientation, the metallothionein promoter/regulator fused to the herpes simplex
virus thymidine kinase gene, cloned into the Barn HI site of pBXO (7). The presence of
the plasmid was ascertained in each mouse by dot blotting. The 419 line is homozygous
for pMKSV and is of C57BL/6J origin, while the 427 line was derived from (C57BL/6J
X SJL/J)F2 mice crossed inter se. The H-2 type of each 427-line mouse was determined
by assaying the reactivity of mouse peripheral blood lymphocytes with H-2-specific
monoclonal antibodies in indirect immunofluorescence. C57BL/6J and (C57BL/6J X
SJL)F, mice served as controls for these experiments .
Antibody Response to SV40 T.
￿
Mice were bled by cardiac puncture and sera were tested
undiluted and at 1 :5, 1 :25, and 1 :125 dilutions on -20°C acetone-fixed coverslips of
SV40-transformed (LB10SV) and control (BALB 3T3) mouse cell lines in indirect im-
munofluorescence. FITC-labeled goat IgG anti-mouse IgG (heavy and light chain-
specific) served as the developing reagent (11). Pooled sera from C57BL/6J mice,
repeatedly immunized with a syngeneic SV40-transformed cell line served as a positive
control, and normal C57BL/6J serum served as a negative control. For detection of SV40
"f antigen by indirect immunofluorescence, acetone-fixed monolayer cultures were re-
acted as above with culture supernatants from 503-31 cells that produce a monoclonal
antibody that reacts with an epitope of SV40 T antigen (6).
51Cr-release Assay.
￿
106 target cells were labeled by overnight incubation with 100 ,ACi
Na5 'Cr in 4 ml Dulbecco's modified Eagle's medium supplemented with 10% FCS and 5
X 10-5 M 2-ME (DME+). The "Cr-release assay was carried out in DME' by coincubation
of radiolabeled target cells with effector cells, in triplicate, at the specified ratios for 4-6
h as previously described (12). Percent specific lysis was calculated as: [(experimental 5 'Cr
release) - (spontaneous "Cr release)]/[(maximum 5 'Cr release) - (spontaneous "Cr
release)] X 100, and standard deviations of triplicates were determined. Spontaneous "Cr
release for each target was always <10% .
Cell Lines.
￿
A cytotoxic T cell line, CTB6, which recognizes an epitope of SV40 T
antigen in association with H-2K' (6) was used as an effector cell in some 5 'Cr-release
assays. The target panel for the 5'Cr-release assays included the following cells: PMK79SV
and PMK79SV-NT, both H-2''", are cell lines derived from 427-line mice by the in vitro
passage of cells from adherent thymus tissue, and by the in vitro cultivation of choroid
plexus tumors passaged through nude mice, respectively; MC57G (H-2b
) is a stable
fibroblastic cell line derived from a methylcholanthrene-induced tumor of a C57BL/6
mouse (12) ; the SV40-transformed cell lines, SSSV (H-26) LgC57SV and LB 10SV (H-26),
KD2SV (H-2d), and (b X s)F,SV (H-2"s) were all derived in vitro by SV40 infection (12) .
Cultures of epithelial cells from the choroid plexus, thymus, and kidney of 419-line mice
were prepared from tissue minces explanted in Eagle's MEM containing 10% FCS and 10
ng/ml epidermal growth factor (EGF culture grade; Collaborative Research, Lexington,
MA).
Cytotoxic T Lymphocytes (CTL) Response to SV40 T Antigen.
￿
Transgenic (419- and 427-
line mice) and control mice [C57BL/6J and (C57BL/6J X SJL)F,] were immunized in the
hind footpads with 10' plaque-forming units (PFU) of SV40 (12); in some experiments,
mice were immunized again 5 wk later with the same dose of SV40. Popliteal lymph node
cells obtained 7 d after immunization were gently dissociated, washed, and plated at 2-3
X 10' cells/well in 24-well plates (Linbro Chemical Co., Hamden, CT). After 4 d in
culture, the cells were harvested and assayed for cytotoxicity in a
51 Cr-release assay with
the panel of target cells described above. Splenocytes removed from the same mice were
restimulated in vitro by cocultivation with irradiated (8,000 rad) s.Zngeneic SV40-trans-
formed stimulator cells for 6 d at a ratio of 10' spleen cells to 10- stimulator cells (12,
13), and then harvested and tested against the full panel of 5'Cr-labeled target cells. All
cell cultures and assays were performed in DME+.
CTL Response to Vaccinia Virus.
￿
Transgenic (427- and 419-line mice) and control mice
(C57BL/6J) were immunized with 5 X 106 PFU vaccinia virus, administered intravenously
as previously described (14). Spleens were removed 10 d later; half of these cells were
infected with vaccinia virus, washed, and used to restimulate equal numbers of uninfectedFAAS ET AL .
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TABLE I
TumorFormation and Response ofpSV-MK Transgenic Mice to
SV40 Immunization
Trans-
￿
SV40T anti-
￿
SV40-specific CTL activity¢
enic line
￿
T g
umors* body* Lymph node
￿
Spleen
427 96/96 0/12 0/9 0/9
419 1/53 3/14 10/14 10/14
* Thenumber ofanimals that develop tumorsper total animals monitored .
Mice were bled by cardiac puncture and their sera tested for reactivity
with SV40-transformed target cells in indirect immunofluorescence as
described in Materials and Methods . Data represent the number of
seropositive mice per total number tested . Data were analyzed by the
Fisher exact probability test p = 0.186 .
§ Transgenic and control mice were immunized with 10' PFU SV40 .
Popliteal lymph node cells obtained 7 d later were cultured for 4 d and
assayed on apanel of "Cr-labeled target cells; splenocytes removed from
the same mice were restimulated by cocultivation with irradiated syn-
geneic SV40-transformed cells for 6 d, harvested, and tested on the
panel of "Cr-labeled target cells . Data represent the number of SV40
responsive animals per total animals tested .
splenocytes by coculture in vitro for 6 d (10" cells total) . Cells were harvested and tested
for cytotoxicity against syngeneic vaccinia-infected or noninfected "Cr-labeled target cells
in an 8-h "Cr-release assay (14) .
Results
Two lines of SV40-transgenic mice were used in this study. Mice of the 427
line develop tumors of the choroid plexus, and approximately one-third of these
mice also develop thymic hyperplasia (7, 9) . Of96 427-line mice monitored until
their death, which occurs between 2 and 8 mo of age, 95 succumbed to choroid
plexus tumors ; the remaining mouse died with a thoracic tumor. In contrast,
only one of 53 mice of the 419 line monitored for up to I yr developed a tumor ;
this tumor was also of the choroid plexus (Table I) . Because the SV40 T antigen
gene copy number and mRNA levels appear to be approximately the same in
nonneoplastic liver tissues from mice ofboth transgenic lines (7), we compared
them for their ability to mount an immune response to SV40 .
Since antibody production to most antigens, including SV40 T antigen (11),
requires T cell participation, functional immune tolerance can be manifested at
the B or T cell level (15) . We screened the sera from a series of 427- and 419-
line mice for the presence of antibodies to SV40T antigen to determine whether
these mice reacted to their endogenous SV40 gene products . None of these
animals, which ranged in age from 2 to 4 mo (427 line) or from 5 to 10 mo (419
line), exhibited visible tumors at the time of testing . No antibodies to SV40 T
antigen were detected in any of the twelve 427-line mice tested ; however, sera
from three of the fourteen 419-line mice assayed gave the nuclear fluorescence
characteristic of SV40 T antigen when reacted with SV40-transformed cell lines
(Table 1) . These three positive sera derived from 6-, 7-, and 8-mo-old mice,
respectively ; samples from seven mice at 5 mo of age, three mice at 10 mo of
age, one mouse aged 6 mo and oneaged 8mo were either negative or unreadable420
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FIGURE 1 . Lymph node cells from SV40-immunized 419-line but not 427-line mice lyse
SV40-transformed target cells. 427-line, 419-line, and control mice [C57BL/6J or (C57BL/6J
X SJL/J)F,] were immunized with SV40 . (A) "Cr-release assay of lymph node cells after a
single SV40 immunization . Reactivity of lymphocytes from SV40-immunized 427-line mice
with SV40 transformed LgC57SV cells (filled circles) or control MC57G cells (open circle) ;
reactivity of lymphocytes from SV40-immunized 419-line mice with LgC57SV cells (filled
triangles) or MC57G cells (open triangle); reactivity of lymphocytes from SV40-immunized
control (C57BL/6J X SJL/J)F, mice with LgC57SV (filled squares) or MC57G (open square) .
(B) "Cr-release assay of spleen cells following restimulation in vitro . Lymphocytes from SV40-
immunized 427-line mice assayed on LgC57SV cells (filled circles) or MC57G cells (open
circle); lymphocytes from SV40-immunized 419-line mice assayed on LgC57SV target cells
(filled triangles) or MC57G cells (open triangle) ; lymphocytes from C57BL/6J assayed on
LgC57SV target cells (filled squares) or MC57G cells (open square) . In both A and B, results
from individual animals are lotted . Similar results were obtained with the other syngeneic
SV40-transformed cells (H-2 or H-2b,,) in the target panel ; the allogeneic SV40-transformed
cell line (H-2 d) in the panel was not lysedby any effector cell shown . MC57G cells were tested
at every effector/target cell ratio ; data are shown for highest ratio only .
due to high nonspecific nuclear reactivity of the serum sample . Detection of
antibody reactivity at a given time in these serum samples is a function of the
time of expression ofSV40 T antigen in the mouse and the level of circulating
antibody, a parameter itself dependent on both restimulation and/or absorption
of antibody by antigen-expressing cells . Therefore these data indicate that SV40
T antigen is expressed in some mice of the 419 line, and these mice are
immunoresponsive to this protein .
The immunologic potential of mice from both transgenic lines was further
evaluated by comparing their ability to generate CTL specific for SV40 T
antigen upon immunization with SV40 . Lymph node cells from 427-line mice
were unable to lyse syngeneic SV40-transformed target cell lines before immu-
nization (not shown), or after primary in vivo SV40 immunization (Fig. 1 A) . In
contrast, immune lymph node cells from 419-line mice lysed syngeneic SV40-
transformed target cells with the same high efficiency as control C57BL/6 mice
(Fig . 1A) . Spleen cells from these animals were restimulated in vitro by coculture
with irradiated SV40-transformed cells to enrich for a population of SV40-
specific T cells . When tested for cytotoxicity against the panel of target cells,
splenic lymphocytes from 427-line mice were unable to lyse syngeneic SV40-
transformed targets (Fig . 1B). Restimulated splenocytes from 419-line and con-
trol C57BL/6J mice, however, demonstrated comparably high levels of H-2-N
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FIGURE 2 . Mice of the 427 line do not generate CTL in response to multiple SV40
immunization . (A) Lymph node-derived cells from 427-line (H-26) mice immunized twice with
SV40 assayed on "Cr-labeled LgC57SV (filled circles) or MC57G (open circle) cells, or from
similarly immunized C57BL/6J mice, assayed on LgC57SV (filled squares) or MC57G (open
square) "Cr-labeled target cells . (B) Splenocytes from animals immunized twice with SV40
were removed 7 d after the second SV40 immunization, and cocultured in vitro with irradiated
PMK79SV cells for 6 d before assay on "Cr-labeled target cells . Splenocytes from 427-line
(H-2 6) mice assayed with LgC57SV (filled circles) or MC57G (open circles) ; splenocytes from
C57BL/6J mice assayed with LgC57SV (filled squares) or MC57G (open square) . Data shown
are from individual mice; similar results were obtained with all syngeneic SV40-transformed
cells in the complete target panel ; neither allogeneic SV40-transformed cell lines nor MC57G
cells were lysed at any of the effector/target cell ratios tested .
restricted SV40-specific target cell lysis (Fig . 1B) . Although we cotjld not dem-
onstrate immune responsiveness in every 419-line animal tested (Table 1), we
found no correlation between immune responsiveness and the sex of the 419-
line mice or their age at immunization ; two of the four unresponsive mice were
males, two were females, each was 5 mo old, and the age of the SV40-responsive
mice ranged between 5 and 10 mo .
To address the possibility that 427-line mice were not tolerant to SV40 but
instead possessed SV40-specific T cells in a frequency too low to be detected by
our immunization protocol, we immunized 427-line and control C57BL/6J mice
twice in vivo over a 5-wk period . Splenocytes from these animals were further
restimulated in vitro with irradiated SV40-transformed cells to provide the
opportunity for maximal expansion ofany SV40-specific T cells present . When
tested for cytotoxicity against the target panel, both lymph node cells (Fig . 2A)
and restimulated splenocytes (Fig . 2B) from these immunized 427-line mice were
unable to lyse SV40-transformed target cell lines at any effector/target cell ratio
tested ; C57BL/6J control mice demonstrated efficient SV40-specific target cell
lysis .
To determine whether mice of the 427 line are specifically tolerized to SV40
or are incapable of generating functional CTL to any antigen, we immunized
transgenic (427- and 419-line mice) and control mice (C57BL/6J) with vaccinia
virus and evaluated their cytotoxic response to vaccinia-infected target cells in
an 8-h "Cr-release assay . 427-line mice were fully capable of generating splenic
CTL that efficiently lysed syngeneic vaccinia-infected target cells (Fig . 3) . The422
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FIGURE 3.
￿
Mice of the 427 and 419 transgenic lines and C57BL/6J control mice are equally
responsive to vaccinia virus immunization . Splenocytes, from mice immunized in vivo and
restimulated in vitro with vaccinia virus, assayed on "Cr-labeled LB10SV cells which were
(closed symbols) or were not (open symbols) infected with vaccinia virus : 427-line mice (circles) ;
419-line mice (triangles) ; C57BL/6J mice (squares) . All immunized mice were H-26; LBIOSV
is an H-26 SV40-transformed cell line .
degree of lysis of infected target cells was comparable to that achieved by 419
line and C57BL/6 immunized Splenocytes; uninfected target cells were not lysed
by any effector group (Fig . 3) . It is noteworthy that the vaccinia-infected and
noninfected cell lines used as targets are the same SV40-transformed cell lines
used in the usual SV40 target cell panel, indicating that immune cells from 427-
line mice are capable of lysing these cells if directed to an antigen other than
SV40 .
To determine whether SV40 T antigen is expressed in the tolerant 427-line
mice in an immunologically recognizable form, we isolated cells from two mice
of the 427 line and assayed them after they became established transformed cell
lines. Both of these cell lines express serologically detectable SV40 T antigen
(Fig . 4A), as do transgenic tissues examined by Western blot analysis (7) . We also
tested whether these isolated cell lines could be lysed byCTL specific for SV40
T antigen . Both cell lines are lysed by SV40-immune Splenocytes from C57BL/6J
mice (Fig. 4B) and by CTB6, a CTL clone that recognizes an epitope of SV40
T antigen expressed at the cell surface in association with the H-2Kb molecule
(Fig . 4C) . The range of specific lysis of these target cells in multiple experiments
is comparable to that achieved using target cell lines conventionally transformed
by SV40 ; furthermore, they are not lysed by H-2-incompatible SV40-specific
effector cells (data not shown) . We have also prepared primary cultures from a
419-line mouse to determine whether cells from these mice could express SV40FAAS ET AL .
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FIGURE 4 .
￿
Expression of SV40 T antigen in cell lines derived from SV40-transgenic tissues .
(A) SV40 nuclear T antigen detected by indirect immunofluorescence of cell line PMK79SV
(right) . BALB 3T3 cells incubatedunderthesame conditions served as a negative control (left) .
(B) SV40-immune splenocytes specifically lyse "Cr-labeled target cell lines from 427-line SV40-
transgenic mice . Splenocytes from aC57BL/6J mouse immunized with SV40 were restimulated
in vitroand tested for cytotoxic activity againsta panel of "Cr-labeled target cell lines derived
from normal and SV40-transgenic mice at the effector/target cell ratios indicated . (C) A
cytotoxic T cell clone, CTB6, which recognizes an epitope of SV40 T antigen in association
with H-2K° , was tested against thesame panel of "Cr-labeled target cell lines .
T antigen in vitro . A few of the cells arising in these primary cultures express
SV40 T antigen . A cell line of epithelial morphology was established from the
outgrowth of a 419 kidney explant . This cell line is susceptible to lysis by SV40-
specific CTLs (data not shown) . Thus, cell lines obtained from tissues of both
427-line and 419-line mice express SV40 T antigen in an immunologically
recognizable form .
Discussion
We have evaluated a panel of mice from two distinct SV40 transgenic lines for
their ability to mount an immune response to SV40 . Mice from both the 427
and 419 lines bear identical plasmid constructs in approximately the same gene
copy number per cell as in normal tissues ; however, these mice differ markedly
both in the incidence of spontaneous tumors, which express detectable levels of
SV40T antigen, and in their ability to generate antibodies and CTL specific for
this viral gene product .
Mice tested from the tumor-prone 427 line are completely unresponsive to
immunization with SV40 . These mice respond normally to immunization with
vaccinia virus, indicating that they are functionally immunocompetent but are
specifically tolerant to SV40 T antigen . In contrast, the majority of mice from
the 419 line mount a normal immune response to SV40 T antigen compared
with nontransgenic control mice .424
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Immune tolerance is a somatically acquired trait (16) thought to result from
events occurring in the thymus during T cell maturation (17, 18) . Thus the
developmental timing of initial expression of SV40 T antigen, the tissue distri-
bution of cells bearing the antigen, and the amount of protein synthesized may
all contribute to the functional outcome, immune tolerance or responsiveness to
SV40 T antigen, in these transgenic mice . The observation that the thymus is
one of the target organs for SV40 T antigen expression in these mice (7, 9), and
that cells derived from a 427-line thymus can be lysed by SV40 T antigen-
specific CTL (Fig. 4, B and C), suggests ready exposure of differentiating
thymocytes to the viral protein in these animals . Their profound immune
tolerance to SV40 T antigen may be mediated by the active participation of
antigen-specific suppressor T cells (19, 20), or alternatively, may be the result of
elimination of antigen-specific T cells (17, 21) during selection of the T cell
repertoire in the thymus early in development . Expression of SV40 T antigen
during fetal development is still under active investigation in both the 427 and
419 lines . Such an analysis may help delineate the cellular mechanisms involved
in the induction ofimmune tolerance to SV40 in 427-line mice, and may define
the differences that allow most 419-line mice to respond normally to immuniza-
tion with SV40 . SV40 T antigen is immunohistochemically detectable within
sporadic cells of the thymic epithelium in 14-d-old 427-line mice and within the
choroid plexus and kidney by 28 d of age (A . Messing, University of Wisconsin,
Madison, W1, personal communication) . SV40 T antigen has not been previously
detected in 419-line mice before 32 wk of age . At this time, low levels of T
antigen were found in the kidney, but not the brain or thymus, by immunopre-
cipitation (22) . Our antibody data demonstrates that SV40 is expressed and
immunologically recognized within some 419-line mice by 6 mo of age. The
sensitivity of detection of minimal numbers of SV40 T antigen-positive cells by
these various techniques differs widely . Low levels of SV40 T antigen detected
by immunoprecipitation from an intact organ can be ascribed to the presence of
but a few SV40 T antigen-expressing cells in the intact organ, or ofa majority
of cells each expressing at a low level . By the former interpretation, low-level
expression in the seemingly normal tissues of 419-line mice relative to that in
transgenic tumor tissue could result from active elimination of SV40T antigen-
positive cells as they arise, or from an inherent inability of these cells to progress
in vivo . Cell lines derived from 419-line mice express ample levels of SV40 T
antigen, and this molecule is not defective (22) .
Theexpression ofSV40Tantigen in 419- and 427-line mice is likely a function
of sequences contained within the inserted construct and of flanking cellular
sequences . Tissue-targeted expression of several genes hasbeen shown to depend
on specific regulatory enhancer sequences (8, 23-25) ; the targeting of SV40
tumor formation to a specific tissue in the transgenic mice used in this study is
influenced by the regulatory sequences of the gene construct used (9) . The 72-
bp SV40 enhancer appears to target abnormalities to the choroid plexus and
perhaps kidney and thymus (7, 9) . The gene construct used to generate both the
427- and 419-lines contains this enhancer sequence . Since the chromosomal site
of gene insertion is random in the founder mice of each line, flanking cellular
sequences may contribute to the differences in SV40 T antigen expression,FAAS ET AL.
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tumor formation, and immune responsiveness to SV40 observed between the
two transgenic lines .
The relationship between cellular immunity to SV40T antigenandthe control
of SV40-transformed cell growth in the mouse has been suggested previously
(2-5) . SV40 injection into young immunocompetent animals results in tumor
appearance late in life in low-responder but not high-responder H-2-congenic
strains (3) . SV40-transformed cell lines are usuallynontumorigenicwhen injected
into syngeneic adult animals, yet they form tumors when injected into neonatal
mice before 24 h of birth (1) . In addition, loss of expression of the H-2 restriction
element on passaged cell lines positively correlates with the ability of these cell
lines to form tumors in adult mice (2, 4) . The demonstration that (a) expression
ofendogenous SV40 early region genes can occur in the absence of overt tumor
formation (reference 7 and this report), and (b) that those animals succumbing
to spontaneous tumors are specifically tolerized to SV40 T antigen and cannot
respond when immunized with the virus suggests that the immune response can
have a controlling influence on the development oftumors associated with this
viral transforming gene product .
Summary
The ability to mount an immune response to simian virus 40 (SV40) T antigen
was evaluated using mice from two distinct SV40 transgenic lines derived from
injection of thesame gene construct . Our studies demonstrate functional immune
tolerance to SV40T antigen in aSV40 transgenic line that consistently develops
tumors of the choroid plexus by 7 mo ofage . Antibodies to SV40T antigen are
undetectable in the serum of these animals ; furthermore, mice from this line are
unable to generate SV40-specificCTL after primary or secondary immunization
with the virus, although they mount a normal CTL response to vaccinia virus
when appropriately immunized. In contrast, we find that mice from a second
transgenic line of low tumor incidence can mount a humoral response to SV40
T antigen, and upon immunization they generally respond with a vigorous
cytotoxic T cell response to SV40 T antigen . These data suggest that specific
immune tolerance to the product ofan integrated viral oncogene maybe induced,
and is likely a reflection of the time in development at which the gene product
first appears . Immune tolerance or responsiveness to the endogenous oncogene
product may in turn play a role in the tumorigenic potential of such genes .
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